Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer. 2008 Mar 15; 112(6):1288-95.
-
Adult
-
Aged
-
Aged, 80 and over
-
Alemtuzumab
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antibodies, Neoplasm
-
Antineoplastic Combined Chemotherapy Protocols
-
Disease-Free Survival
-
Female
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell
-
Male
-
Maximum Tolerated Dose
-
Middle Aged
-
Rituximab
-
Survival Rate
-
Vidarabine